Showing session: reset
Proffered Paper Session 1
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner.
Poulikos I. Poulikakos
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non small cell lung cancer
Sarah Bacus
Quintiles Transnational Corp., Westmont, IL, United States
- Free
- audio only
- Audio only
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a Phase II clinical trial of Pertuzumab and Erlotinib
Elizabeth Punnoose
Genentech, Inc., South San Francisco, CA, United States
- Free
- audio + slides
- Some slides withheld
Gene amplification of Anaplastic Lymphoma Kinase in Inflammatory Breast Cancer
Fredika M. Robertson
UT MD Anderson Cancer Ctr., Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
GATA2 is required for oncogene-driven non-small cell lung cancer
MADHU S KUMAR
CRUK LONDON RESEARCH INSTITUTE, LONDON, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Pharmacodynamic analysis of ENCORE 301, a placebo controlled, randomized phase 2 study of exemestane with and without entinostat in postmenopausal ER+ breast cancer patients demonstrates an association of lysine hyperacetylation with clinical outcome
Peter Ordentlich
Syndax Pharmaceuticals, Inc., Waltham, MA, United States